Hikma dominates trading

Yesterday’s trading leader was Hikma Pharmaceuticals, a drugmaker focusing on producing and marketing generics. The group had previously provided rather gloomy guidance for 2016, yet its results have contradicted them. Indeed, Hikma reported a revenue of approximately $1.95bn, meeting expectations by Bloomberg experts, that is $2bn. EBITDA decreased by 9% – that is $302m, far exceeding the expected $281m. Hikma’s shares, traded in London, rose more than 7% yesterday, reaching a market value of GBP5.43bn.
(Source: Yahoo Finance)